Biogen down 3% after hours on Mylan patent challenge Seeking Alpha
Biogen (BIIB) slips 3% after hours in apparent response to a decision from the USPTO’s Patent Trial and Appeal Board allowing an inter partes review of cer.
Biogen down 3% after hours on Mylan patent challenge Seeking Alpha
Biogen (BIIB) slips 3% after hours in apparent response to a decision from the USPTO’s Patent Trial and Appeal Board allowing an inter partes review of cer.